A5000127691- Acute Lymphoblastic Leukemia research
- Acute Myeloid Leukemia Research
- Childhood Cancer Survivors' Quality of Life
- Chronic Myeloid Leukemia Treatments
- Parvovirus B19 Infection Studies
- Neuroblastoma Research and Treatments
- Sarcoma Diagnosis and Treatment
- Immunodeficiency and Autoimmune Disorders
- Central Venous Catheters and Hemodialysis
- Axon Guidance and Neuronal Signaling
- Chemotherapy-related skin toxicity
- interferon and immune responses
- Prenatal Screening and Diagnostics
- Histiocytic Disorders and Treatments
- Zebrafish Biomedical Research Applications
- Hematopoietic Stem Cell Transplantation
- Immune Cell Function and Interaction
- Cancer, Hypoxia, and Metabolism
- Autoimmune and Inflammatory Disorders Research
- T-cell and B-cell Immunology
- Neutropenia and Cancer Infections
Huntsman Cancer Institute
2025
Primary Children's Hospital
2013-2025
University of Utah
2007-2025
Alfred I. duPont Hospital for Children
2020-2022
Center for Cancer and Blood Disorders
2020-2022
St. Jude Children's Research Hospital
2017-2022
DuPont (United States)
2021
Albert Einstein College of Medicine
2013
The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Pediatric Acute Lymphoblastic Leukemia (ALL) were developed as a result of meetings convened by multidisciplinary panel pediatric ALL experts, with the goal providing recommendations on standard treatment approaches based current evidence. focus risk assessment and stratification risk-adapted therapy; strategies BCR::ABL1 (Philadelphia chromosome [Ph])-negative -positive B-cell lineage, T-cell infant ALL; supportive care...
Abstract Background: Zilovertamab vedotin (ZV) is an antibody-drug conjugate comprising anti-ROR1 antibody, a proteolytically cleavable linker, and monomethyl auristatin E. Substudy 01A of LIGHTBEAM-U01 (NCT06395103) single-arm, open-label, phase 1/2 basket study designed to determine the preliminary recommended 2 dose (RP2D), safety, antitumor activity ZV in 4 disease cohorts: pediatric patients (pts) with relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL), diffuse large...
Alterations in the IKZF1 gene drive B-cell acute lymphoblastic leukemia (B-ALL) but are not routinely used to stratify patients by risk because of inconsistent associations with outcomes. We describe a novel deletion 22q11.22 that was consistently associated very poor outcomes B-ALL alterations.To determine whether focal deletions within λ variable chain region chromosome were alterations highest relapse and/or death.This cohort study included 1310 primarily high-risk pediatric who taken...
Background While there is increasing evidence supporting the choice of subcutaneous ports (SPs) over external venous catheters (EVCs) in pediatric oncology patients, prior conflicting studies exist and little data have been gathered as to which type central line preferred from patient/family perspective. Procedure We performed a single institution, 10 years, retrospective analysis lines patients (n = 878) evaluate unplanned early removal cause while simultaneously obtaining cross sectional...
Abstract Approximately 25% of B‐cell acute lymphoblastic leukemia (B‐ALL) cases are defined by hyperdiploidy, with RAS mutations occurring in 30% hyperdiploid B‐ALL patients. It is believed that hyperdiploidy an utero event postnatally, but clinical evidence this based on relatively few We present a case monozygotic, monochorionic twins who developed concordant identical chromosomal gains different mutations, adding further prenatally, developing postnatally. Environmental exposures were...
In this report, we describe the case of an adolescent male with unusual fusion-negative, paratesticular alveolar rhabdomyosarcoma who presented spontaneous tumour lysis syndrome and diffuse bony metastases throughout axial appendicular skeleton additional significant bone marrow involvement. Both are extremely for rhabdomyosarcoma. On backbone standard vincristine, dactinomycin cyclophosphamide (VAC) chemotherapy, only local control was orchiectomy at 15 weeks, no radiation administered due...
Summary Of 1003 children with acute lymphoblastic leukaemia (ALL), 147 (14.7%) presented without peripheral blood blasts (PBB). While absence of PBB was not independently associated survival outcomes when compared to those PBB, patients had distinct genetic and clinical characteristics. Notably, we identified a novel genotype–phenotype relationship, in that the significantly higher incidence hyperdiploid B‐ALL, accounting for almost half all (46.9% vs. 22.7%, p < 0.001). Further,...